Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud. You can reach Allison on Signal at AllisonDeAngelis.01.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

How did Terns Pharmaceuticals and its “hodgepodge” pipeline grab attention at the American Society of Hematology conference? Is Eli Lilly’s new drug making people lose too much weight? And what, exactly, is the Trump administration’s plan for reforming the National Institutes of Health?

We discuss all that and more on “The Readout LOUD,” STAT’s weekly biotech podcast. 

Advertisement

First, we discuss all things ASH, particularly Tern’s chronic myeloid leukemia dataJohnson & Johnson’s multiple myeloma data, and Fulcrum Therapeutics’ pill for sickle cell disease. We also get into the latest news in — what else? — obesity drugs

Then, STAT reporters Megan Molteni and Anil Oza join for a conversation on the new series “American Science, Shattered,” which details this fissure and what it means for the future of the country’s scientific institutions. 

Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts. Tune in next week for the last episode of 2025!

Advertisement